Medical treatment of cardiovascular diseases in patients after hospitalization for COVID-19 (three-year follow-up data in the TARGET-VIP registry)
Authors:
- N. P. KutishenkoNKN. P. Kutishenko
- S. Yu. MartsevichSMS. Yu. Martsevich
- M. M. LoukianovMLM. M. Loukianov
- E. Yu. AndreenkoEAE. Yu. Andreenko
- V. P. VoroninaVVV. P. Voronina
- V. A. DindikovaVDV. A. Dindikova
- N. A. DmitrievaNDN. A. Dmitrieva
- M. M. KudryavtsevaMKM. M. Kudryavtseva
- O. V. LermanOLO. V. Lerman
- E. Yu. OkshinaEOE. Yu. Okshina
- A. A. SmirnovASA. A. Smirnov
- A. G. SoplenkovaASA. G. Soplenkova
Open Access
- 29 December 2024
- journal article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (6) , 637-644
Abstract
Aim. To evaluate the quality of drug treatment of patients with cardiovascular diseases (CVD) at the remote stage of follow-up after hospitalization for new coronavirus infection (COronaVIrus Disease 2019, COVID-19) within the framework of the prospective TARGET-VIP registry.Material and methods. 1,130 people were included in the registry. The 473 (54.8%) patients with CVD were selected of the 863 patients discharged from the hospital with a diagnosis of COVID-19.Results. The frequency of proper prescriptions of medicines upon discharge from the hospital was 60%, after 3 years this indicator decreased to 41.4% (pConclusion. The quality of CVD therapy was insufficient at all stages of long-term follow-up: the frequency of proper prescriptions upon discharge from the hospital was 60%, after 3 years this indicator decreased to 41.4%. A clear trend was revealed in a decrease in the frequency of taking all drugs, while for some groups of drugs this decrease reached statistically significant differences. The quality of cardiovascular pharmacotherapy was higher with the appearance / development of new CVD in comparison with the group of stable patients with CVD, there was no significant improvement in the quality of therapy for previously observed CVD.Keywords
This publication has 21 references indexed in Scilit:
- Barriers and enablers to implementing clinical practice guidelines in primary care: an overview of systematic reviewsBMJ Open, 2023
- Long-term cardiovascular outcomes of COVID-19Nature Medicine, 2022
- Global pandemics interconnected — obesity, impaired metabolic health and COVID-19Nature Reviews Endocrinology, 2021
- Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-AnalysisJournal of Community Health, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- American Heart Association COVID-19 CVD Registry Powered by Get With The GuidelinesCirculation: Cardiovascular Quality and Outcomes, 2020
- Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 DiabetesCell Metabolism, 2020
- Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-AnalysisAging and disease, 2020
- Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: Results from the antiplatelet treatment observational registries (APTOR)International Journal of Cardiology, 2013
- Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological surveyThe Lancet, 2011